Stock Track | Align Technology Soars 10.2% After Hours on Q1 Earnings Beat and Strong Outlook

Stock Track
2025/05/01

Shares of Align Technology (NASDAQ: ALGN) surged 10.2% in after-hours trading on Thursday following the release of the company's first quarter 2025 financial results that exceeded analyst expectations and provided an optimistic outlook for the year ahead.

The dental medical device company, known for its Invisalign clear aligners, reported adjusted earnings per share of $2.13, surpassing the analyst consensus estimate of $1.99 by 7.04%. While this represents a slight 0.47% decrease from the same period last year, it showcases Align's ability to maintain strong profitability in a challenging environment. Revenue for the quarter came in at $979.3 million, beating the analyst estimate of $975.2 million, despite showing a marginal 1.82% decrease year-over-year.

Investors were particularly encouraged by several key operational highlights: 1. Clear Aligner volume increased 6.2% year-over-year to 642,305 cases, indicating strong demand for Align's core product. 2. Clear Aligner volume for teens and growing patients rose 13.3% year-over-year, suggesting successful market penetration in this important demographic. 3. The company reported growth across all regions, with particular strength in Asia Pacific and EMEA. Additionally, Align Technology provided a positive outlook for the full year 2025, projecting revenue growth between 3.5% and 5.5%. This forward-looking guidance suggests confidence in the company's ability to drive growth despite economic uncertainties.

Align Technology CEO Joe Hogan commented on the results, stating, "Fiscal 2025 is off to a good start with Q1 Clear Aligner volumes up both sequentially and year-over-year, reflecting strength in both the teens and adult patient segments, across all regions."

The strong quarterly performance, coupled with an optimistic future outlook, likely contributed to the significant after-hours stock price surge as investors reassessed the company's value proposition in the competitive dental technology market.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10